nach oben

Erschienen in:

01.05.2009 | Original Article

Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label

verfasst von: William H. Shrank, MD, MSHS, Patrick P. Gleason, Pharm. D., Claire Canning, MA, Carol Walters, MBA, Alan H. Heaton, Pharm. D., Saira Jan, Pharm. D., Amanda Patrick, MS, M. Alan Brookhart, PhD, Sebastian Schneeweiss, MD ScD, Daniel H. Solomon, MD MPH, Jerry Avorn, MD, Niteesh K. Choudhry, MD PhD

Erschienen in: Journal of General Internal Medicine | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

BACKGROUND

Prescription medication labels contain valuable health information, and better labels may enhance patient adherence to chronic medications. A new prescription medication labeling system was implemented by Target pharmacies in May 2005 and aimed to improve readability and understanding.

OBJECTIVE

We evaluated whether the new Target label influenced patient medication adherence.

DESIGN AND PATIENTS

Using claims from two large health plans, we identified patients with one of nine chronic diseases who filled prescriptions at Target pharmacies and a matched sample who filled prescriptions at other community pharmacies.

MEASUREMENTS

We stratified our cohort into new and prevalent medication users and evaluated the impact of the Target label on medication adherence. We used linear regression and segmented linear regression to evaluate the new-user and prevalent-user analyses, respectively.

RESULTS

Our sample included 23,745 Target users and 162,368 matched non-Target pharmacy users. We found no significant change in adherence between new users of medications at Target or other community pharmacies (p = 0.644) after implementing the new label. In prevalent users, we found a 0.0069 percent reduction in level of adherence (95% CI −0.0138-0.0; p < 0.001) and a 0.0007 percent increase in the slope in Target users (the monthly rate of change of adherence) after implementation of the new label (95% CI 0.0001–0.0013; p = 0.001).

CONCLUSIONS

We found no changes in adherence of chronic medication in new users, and small and likely clinically unimportant changes in prevalent users after implementation of the new label. While adherence may not be improved with better labeling, evaluation of the effect of labeling on safety and adverse effects is needed.

Nur mit Berechtigung zugänglich

World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: WHO; 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf Accessed 1/26/09.

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRef

Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458–62.PubMedCrossRef

Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836–41.PubMedCrossRef

National Council on Patient Information and Education. Enhancing prescription medication adherence: a national action plan. Aug. 2007. Available at: http://www.talkaboutrx.org/documents/enhancing_prescription_medicine_adherence.pdf. Accessed 6/2/2008.

Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11(14):1665–70.PubMedCrossRef

Isaac LM, Tamblyn RM. Compliance and cognitive function: a methodological approach to measuring unintentional errors in medication compliance in the elderly. McGill-Calgary Drug Research Team. Gerontologist. 1993;33(6):772–81.PubMed

Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med. 2006;166(17):1855–62.PubMedCrossRef

Svarstad BL, Bultman DC, Mount JK. Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness. J Am Pharm Assoc (Wash DC). 2004;44(1):22–9.

10.

Fletcher SW, Fletcher RH, Thomas DC, et al. Patients’ understanding of prescribed drugs. J Community Health. 1979;4(3):183–9.PubMedCrossRef

11.

Shrank WH, Avorn J. Educating patients about their medications: the limitations and potential of written drug information. Health Affairs. 2007;26(3):731–40.PubMedCrossRef

12.

Davis TC, Wolf MS, Bass PF 3rd, Thompson JA, Tilson HH, Neuberger M, Parker RM. Literacy and misunderstanding prescription drug labels. Ann Intern Med. 2006;145(12):887–94.PubMed

13.

Davis TC, Wolf MS, Bass PF 3rd, Middlebrooks M, Kennen E, Baker DW, Bennett CL, Durazo-Arvizu R, Bocchini A, Savory S, Parker RM. Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med. 2006;21(8):847–51.PubMedCrossRef

14.

Shrank WH, Agnew-Blais J, Choudhry NK, Wolf MS, Kesselheim A, Avorn J, Shekelle P. The variability and quality of medication container labels. Arch Intern Med. 2007;167(16):1760–5.PubMedCrossRef

15.

Haynes RB, McDonald H, Garg AX. Interventions for helping patients to follow prescriptions for medications. Oxford, England: Cochrane library, Update software; 2002; issue 2.

16.

Shrank W, Avorn J, Rolón C, Shekelle P. The Effect of the Content and Format of Prescription Drug Labels on Readability, Understanding and Medication Use: a Systematic Review. Annals of Pharmacotherapy. 2007;41(5):783–801.PubMedCrossRef

17.

Bull, G. USA Today. April 28, 2005. Available at: http://www.usatoday.com/money/industries/health/drugs/2005-04-28-target-pill_x.htm?csp = 34. Accessed 01/26/09

18.

Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, Dewees-Dunk R, Levenson S, Kufe D, Craven DE. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92(5):495–502.PubMedCrossRef

19.

20.

Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med. 2006;21(12):1215–21.PubMedCrossRef

21.

Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, Daley WL, Gurwitz J, Hollenberg NK. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48.PubMedCrossRef

22.

Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;(42):121–30.

23.

DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.PubMedCrossRef

24.

Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540–50.PubMedCrossRef

25.

Shrank WH, Asch SM, Adams J, Setodji C, Kerr EA, Keesey J, Malik S, McGlynn EA. The Quality of Pharmacologic Care for Adults in the United States. Medical Care. 2006;44(10):936–45.PubMedCrossRef

26.

Higashi T, Shekelle PG, Solomon DH, Knight EL, Roth C, Chang JT, Kamberg CJ, MacLean CH, Young RT, Adams J, Reuben DB, Avorn J, Wenger NS. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004;140(9):714–20.PubMed

27.

Choudhry NK, Anderson G, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. The impact of adverse events on warfarin prescribing in atrial fibrillation: a matched-pair analysis. BMJ. 2006;332:141–5.PubMedCrossRef

28.

Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–16.PubMedCrossRef

Titel: Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications? An Evaluation of the Target Pharmacy Label
verfasst von: William H. Shrank, MD, MSHS
Patrick P. Gleason, Pharm. D.
Claire Canning, MA
Carol Walters, MBA
Alan H. Heaton, Pharm. D.
Saira Jan, Pharm. D.
Amanda Patrick, MS
M. Alan Brookhart, PhD
Sebastian Schneeweiss, MD ScD
Daniel H. Solomon, MD MPH
Jerry Avorn, MD
Niteesh K. Choudhry, MD PhD
Publikationsdatum: 01.05.2009
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 5/2009
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-009-0924-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

BACKGROUND

OBJECTIVE

DESIGN AND PATIENTS

MEASUREMENTS

RESULTS

CONCLUSIONS

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Symptom Burden, Depression, and Spiritual Well-Being: A Comparison of Heart Failure and Advanced Cancer Patients

Factors Associated with Osteoporosis Screening and Recommendations for Osteoporosis Screening in Older Adults

Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin

Who Gets Disease Management?

Obesity and Mammography: A Systematic Review and Meta-Analysis

Personalizing Health Care—Is This the Right Time for Warfarin?